Emil D. Kakkis
President & CEO at Ultragenyx Pharmaceutical Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Ultragenyx Pharmaceutical Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Ultragenyx Pharmaceutical Inc. May 14, 202698.6%
-
Ultragenyx Pharmaceutical Inc. June 7, 202398.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 16, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +76,745 | — | — |
| Mar 2, 2026 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −54,404 | $22.80 | $1,240,411 |
| Mar 1, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +71,177 | — | — |
| Mar 3, 2025 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −73,434 | $42.10 | $3,091,571 |
| Mar 1, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +43,268 | — | — |
| Mar 1, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +107,292 | — | — |
| Feb 28, 2025 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −25,000 | $42.48 | $1,062,000 |
| Dec 30, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −11,727 | $42.23 | $495,231 |
| Dec 10, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −8,273 | $50.00 | $413,650 |
| Dec 9, 2024 | Ultragenyx Pharmaceutical Inc. | Gift | −20,000 | — | — |
| Sep 3, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −20,000 | $55.85 | $1,117,000 |
| Aug 6, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −20,000 | $50.17 | $1,003,400 |
| Mar 1, 2024 | Ultragenyx Pharmaceutical Inc. | Grant or award | +38,428 | — | — |
| Mar 1, 2024 | Ultragenyx Pharmaceutical Inc. | Shares withheld for tax | −17,417 | $53.69 | $935,119 |
| Mar 1, 2024 | Ultragenyx Pharmaceutical Inc. | Grant or award | +3,132 | — | — |
Questions about Emil D. Kakkis
What boards is Emil D. Kakkis on?
Emil D. Kakkis sits on the board of Ultragenyx Pharmaceutical Inc.
What company is Emil D. Kakkis the CEO of?
Emil D. Kakkis is President & CEO of Ultragenyx Pharmaceutical Inc.
How long has Emil D. Kakkis served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.